Search

Background and Aims: Follitropin delta is the third recombinant FSH (rFSH) preparation developed with an individualized dosing regimen based on patient’s body weight and AMH level. According to the existing report, a daily dose of follitropin delta provides an equivalent ovarian response to that of follitropin alfa. However, the effect of follitropin delta on the resulting embryo and biochemical pregnancy remains to be elucidated. Hence, the present study aims to evaluate the effect of follitropin delta on embryo quality and biochemical pregnancy rates compared with that of follitropin alfa in an in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycle. Methods: A retrospective cohort study was conducted between January and December 2022 at Melati Clinic, Harapan Kita Women and Children Hospital. A total of 59 IVF/ICSI cycles stimulated with follitropin alfa and 26 IVF/ICSI cycles treated with follitropin delta were subsequently analyzed. Results: After analysis, no significant difference was observed regarding the embryo quality of both treatments (P>0.05). The median of the good, moderate, and poor embryos in the follitropin alfa and follitropin delta group was 2 vs. 3, 1 vs. 2, and 2 vs. 2, respectively. Similarly, the biochemical pregnancy rate between the follitropin alfa and follitropin delta group was comparable (25% vs. 15%, P>0.05). Conclusions: In conclusion, our study suggests that stimulation with follitropin delta in IVF/ICSI cycles yields a similar embryo quality and biochemical pregnancy rates to those of follitropin alfa.

Background and Aims: Due to the coronavirus disease-19 (COVID-19) pandemic, assisted reproductive techniqueservices across Indonesia have been suspended. With an unpredictable duration, the suspension is affecting particular groups of women who want to achieve pregnancy, including advanced aged women whose fertility has declined significantly. Here we present a 44-year-old woman with primary infertility and nulliparous with unexplained indication who underwent an in vitro fertilization procedure while confirmed positive for COVID-19. The goal of this study was to investigate SARS-CoV-2 transmission through the embryo and its effect on the embryo survival rate. Method: The IVF procedure was carried out following standard methods. Controlled ovarian stimulation was done by giving growth hormone and exogenous gonadotropin on the first day of the cycle, gonadotropin-releasing hormone antagonist on day 7 of the cycle, and human chorionic gonadotropin 36 hours before ovum pick up. Then, ovum pick up was carried out with COVID-19 standard safety procedures and the follicles were sent to the IVF laboratory with a heating stage. The oocytes were obtained from the follicular fluid analysis, following intracytoplasmic sperm injection. The zygotes were cultured for 48 hours and tested negative for SARS-CoV-2. Afterward, the entire embryos were vitrified for 30 days until the patient’s RT-PCR test confirmed negative for SARS-CoV-2 infection. Thereafter, an endometrial thickness examination was done, followed by embryo transfer on the same day. Results: Six oocytes in metaphase-II were retrieved while the patient was confirmed positive with COVID-19. After fertilization, 6 embryos were obtained, tested negative for COVID-19, and were later vitrified. Conclusion: Two of the embryos survived vitrification and both were successfully transferred. IVF with standard procedures is safe to proceed on COVID-19 positive women.